LS Investment Advisors LLC raised its position in Illumina, Inc. (NASDAQ:ILMN) by 3.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,358 shares of the life sciences company’s stock after buying an additional 115 shares during the period. LS Investment Advisors LLC’s holdings in Illumina were worth $583,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Bank of Montreal Can raised its position in shares of Illumina by 61.0% in the first quarter. Bank of Montreal Can now owns 113,182 shares of the life sciences company’s stock worth $19,314,000 after buying an additional 42,876 shares during the period. National Pension Service raised its position in shares of Illumina by 3.7% in the first quarter. National Pension Service now owns 122,352 shares of the life sciences company’s stock worth $21,186,000 after buying an additional 4,331 shares during the period. Gulf International Bank UK Ltd raised its position in shares of Illumina by 1.4% in the first quarter. Gulf International Bank UK Ltd now owns 45,040 shares of the life sciences company’s stock worth $7,685,000 after buying an additional 600 shares during the period. Forte Capital LLC ADV raised its position in shares of Illumina by 1.6% in the first quarter. Forte Capital LLC ADV now owns 2,185 shares of the life sciences company’s stock worth $373,000 after buying an additional 35 shares during the period. Finally, Chevy Chase Trust Holdings Inc. raised its position in shares of Illumina by 33.0% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 346,451 shares of the life sciences company’s stock worth $59,114,000 after buying an additional 85,922 shares during the period. Institutional investors own 93.75% of the company’s stock.
Shares of Illumina, Inc. (NASDAQ:ILMN) opened at 176.30 on Thursday. The firm has a market capitalization of $25.74 billion, a price-to-earnings ratio of 35.68 and a beta of 0.84. The stock’s 50 day moving average price is $174.86 and its 200-day moving average price is $171.36. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $189.48.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.64. The company had revenue of $598 million during the quarter, compared to the consensus estimate of $590.51 million. Illumina had a net margin of 30.75% and a return on equity of 21.21%. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.71 earnings per share. On average, equities research analysts predict that Illumina, Inc. will post $3.63 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “LS Investment Advisors LLC Has $583,000 Stake in Illumina, Inc. (NASDAQ:ILMN)” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://sportsperspectives.com/2017/07/27/ls-investment-advisors-llc-has-583000-stake-in-illumina-inc-nasdaqilmn.html.
A number of research analysts have issued reports on the company. BidaskClub upgraded Illumina from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Deutsche Bank AG reiterated a “hold” rating and set a $175.00 price target (up previously from $165.00) on shares of Illumina in a research report on Saturday, April 29th. Cowen and Company reiterated an “outperform” rating and set a $200.00 price target on shares of Illumina in a research report on Wednesday, April 26th. Cantor Fitzgerald boosted their price target on Illumina from $155.00 to $170.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 26th. Finally, Vetr lowered Illumina from a “strong-buy” rating to a “buy” rating and set a $195.67 price target for the company. in a research report on Tuesday, April 25th. Four investment analysts have rated the stock with a sell rating, ten have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $167.49.
In other news, Director A Blaine Bowman sold 2,300 shares of the company’s stock in a transaction on Wednesday, May 10th. The shares were sold at an average price of $181.61, for a total transaction of $417,703.00. Following the completion of the transaction, the director now directly owns 18,004 shares in the company, valued at $3,269,706.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Charles Dadswell sold 1,609 shares of the company’s stock in a transaction on Wednesday, May 3rd. The stock was sold at an average price of $187.07, for a total transaction of $300,995.63. Following the transaction, the senior vice president now owns 10,936 shares of the company’s stock, valued at $2,045,797.52. The disclosure for this sale can be found here. Insiders have sold 125,248 shares of company stock valued at $22,281,673 over the last quarter. Company insiders own 1.60% of the company’s stock.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.